S0000 Selenium and Vitamin E in Preventing Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Healthy male volunteers
• Digital rectal examination (DRE) deemed not suspicious for prostate cancer performed within 364 days prior to study entry
• * Participants with a suspicious DRE are ineligible even if a recent or subsequent biopsy is negative for cancer
• Total prostate-specific antigen ≤ 4.0 ng/mL within 364 days prior to study entry
• No prior prostate cancer or high-grade (grade 2-3) prostatic intraepithelial neoplasia
• PATIENT CHARACTERISTICS:
• Age:
• See Disease Characteristics
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• Not specified
• Renal:
• Not specified
• Cardiovascular:
• Systolic blood pressure \< 160 mm Hg
• Diastolic blood pressure \< 90 mm Hg
• No history of hemorrhagic stroke
• Other:
• No malignancies within the past 5 years except basal cell or squamous cell skin cancer
• No uncontrolled medical illness
• No retinitis pigmentosa
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• At least 7 years since prior randomization to SWOG-9217, with completion of end-of-study biopsy requirement
• No additional concurrent selenium or vitamin E (contained in individual supplements, antioxidant mix, or multivitamin)
• Concurrent multivitamins allowed (supplied on study)
• No concurrent anticoagulation therapy (e.g., warfarin)
• Concurrent prophylactic aspirin (average daily dose no greater than 175 mg/day) allowed
• * Concurrent daily aspirin dose ≤ 81 mg for participants receiving clopidogrel
• Concurrent anti-hypertension medication allowed
• No concurrent participation in another study involving a medical, surgical, nutritional, or life-style intervention (unless no longer receiving the intervention and are in the follow-up phase only)